An antibody against CCL2 (CNTO888, Carlumab), investigated in patients with metastatic castration-resistant prostate cancer and patients with solid tumors, or an antibody against CCR2 (MLN1202, Plozalizumab), investigated in patients with RA, was not successful in clinical trials to date [169]. The gene discussed is CCR2; the disease is rheumatoid arthritis.